Related Experiment Videos

Lincocinamides and the incidence of antibiotic-associated colitis

E C Jaimes1

  • 1Center for Research on Infectious Diseases, Institute of Public Health, Cuernavaca, Morelos, Mexico.

Clinical Therapeutics
|March 1, 1991
PubMed

Insights

Antibiotic-associated colitis (AAC) incidence is decreasing. Ampicillin poses the highest risk, followed by cephalosporins and lincocinamides, but vancomycin, metronidazole, or bacitracin are effective treatments.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Pharmacology

Background:

  • Antibiotic-associated colitis (AAC) and pseudomembranous colitis are potential adverse effects of antimicrobial therapy.
  • Lincocinamides and other antimicrobial agents have been implicated in causing colitis.

Purpose of the Study:

  • To review the incidence and risk factors associated with antibiotic-associated colitis.
  • To evaluate the effectiveness of different treatments for antibiotic-associated colitis.

Main Methods:

  • Literature review of reported cases of antibiotic-associated colitis.
  • Analysis of antimicrobial agents and their association with colitis incidence.
  • Review of treatment outcomes for antibiotic-associated colitis.

Main Results:

  • The overall incidence of antibiotic-associated colitis appears to be declining.
  • Ampicillin presents the highest risk for AAC, followed by cephalosporins, then lincocinamides.
  • Vancomycin, metronidazole, and bacitracin demonstrate effectiveness in treating AAC.

Conclusions:

  • While the incidence of AAC is decreasing, vigilance is still required.
  • Understanding the differential risks of various antibiotics is crucial for prevention.
  • Established treatments for AAC are generally effective.

Related Concept Videos